🔴 Crispr Therapeutics is trading 5.3% down today as multi-day decline extends on valuation concerns

Crispr Therapeutics is trading at $53.34 (5.3% down) as the stock extends a multi-day decline following recent CASGEVY label expansion headlines and mixed valuation sentiment.

• Shares have faced sustained pressure, falling 4.8% on July 9 and 2.6% on July 8, as investors reassess bullish analyst targets.
• Market participants are weighing long-term potential against concerns over limited current revenues and ongoing cash burn.
• The downward move reflects broader profit-taking and risk-off positioning within high-beta biotech equities.